RESUMEN

Anti-androgen therapy is the leading treatment for advanced prostate cancer and is commonly used for neoadjuvant or adjuvant treatment. Bicalutamide is a non-steroidal anti-androgen, used during the initiation of androgen deprivation therapy along with a luteinizing hormone-releasing hormone agonist to reduce the symptoms of tumor-related flares in patients with advanced prostate cancer. As side effects, bicalutamide can cause fatigue, gynecomastia, and decreased libido through competitive androgen receptor blockade. Additionally, although not as common, drug-induced liver injury has also been reported. Herein, we report a case of hepatotoxicity secondary to bicalutamide use. Typically, bicalutamide-induced hepatotoxicity develops after a few days; however, in this case, hepatic injury occurred 5 mo after treatment initiation. Based on this rare case of delayed liver injury, we recommend careful monitoring of liver function throughout bicalutamide treatment for prostate cancer.

Asunto(s)

Antagonistas de Andrógenos/efectos adversos , Anilidas/efectos adversos , Antineoplásicos Hormonales/efectos adversos , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Terapia Neoadyuvante/efectos adversos , Nitrilos/efectos adversos , Neoplasias de la Próstata/tratamiento farmacológico , Compuestos de Tosilo/efectos adversos , Biopsia , Enfermedad Hepática Inducida por Sustancias y Drogas/diagnóstico , Enfermedad Hepática Inducida por Sustancias y Drogas/tratamiento farmacológico , Quimioterapia Adyuvante , Humanos , Masculino , Persona de Mediana Edad , Prostatectomía , Neoplasias de la Próstata/cirugía , Factores de Tiempo , Resultado del Tratamiento

RESUMEN

We examined the synergistic effects of CO2 injection on electro-chlorination in disinfection of plankton and bacteria in simulated ballast water. Chlorination was performed at dosages of 4 and 6ppm with and without CO2 injection on electro-chlorination. Testing was performed in both seawater and brackish water quality as defined by IMO G8 guidelines. CO2 injection notably decreased from the control the number of Artemia franciscana, a brine shrimp, surviving during a 5-day post-treatment incubation (1.8 and 2.3 log10 reduction in seawater and brackish water, respectively at 6ppm TRO+CO2) compared with water electro-chlorinated only (1.2 and 1.3 log10 reduction in seawater and brackish water, respectively at 6ppm TRO). The phytoplankton Tetraselmis suecica, was completely disinfected with no live cell found at >4ppm TRO with and without CO2 addition. The effects of CO2 addition on heterotrophic bacterial growth was not different from electro-chlorination only. Total residual oxidant concentration (TRO) more rapidly declined in electro-chlorination of both marine and brackish waters compared to chlorine+CO2 treated waters, with significantly higher amount of TRO being left in waters treated with the CO2 addition. Total concentration of trihalomethanes (THMs) and haloacetic acids (HAAs) measured at day 0 in brackish water test were found to be 2- to 3-fold higher in 6ppm TRO+CO2-treated water than in 6ppm TRO treated water. The addition of CO2 to electro-chlorination may improve the efficiency of this sterilizing treatment of ballast water, yet the increased production of some disinfection byproducts needs further study.

Asunto(s)

Dióxido de Carbono/toxicidad , Desinfección/métodos , Halogenación , Plancton/efectos de los fármacos , Purificación del Agua/métodos , Animales , Bacterias/efectos de los fármacos , Cloro , Desinfectantes , Desinfección/estadística & datos numéricos , Electrólisis , Concentración de Iones de Hidrógeno , Pruebas de Sensibilidad Microbiana , Oxidantes , Fitoplancton , Agua de Mar/microbiología , Navíos

RESUMEN

BACKGROUND: Sorafenib is an orally administered multikinase inhibitor with antiangiogenic and antiproliferative properties. The results of large clinical trials demonstrate that sorafenib prolongs survival and the time to progression of patients with advanced hepatocellular carcinoma (HCC). The aim of the present study was to determine the outcomes of such patients who were routinely treated with sorafenib at multi-institutions in Korea, in contrast to formal clinical trials. METHODS: Between August 2007 and March 2012, patients with advanced HCC in seven referral medical centers in Daejeon-Chungcheong Province of Korea were retrospectively enrolled to evaluate treatment response, survival, and tolerability following administration of sorafenib. The treatment response was assessed in accordance with the Response Evaluation Criteria in Solid Tumor 1.1 guidelines. RESULTS: Among 116 patients, 66 (57%) had undergone treatment for HCC, and 77 (66%) were accompanied with Child-Pugh A cirrhosis. The median duration of sorafenib treatment was 67 days (range 14-452 days). Median overall survival and median time to progression were 141 days and 90 days, respectively. Complete response, partial response, and stable disease were achieved for 0%, 2%, and 29% of patients, respectively. Overall median survival, but not the median time to progression, was significantly shorter for patients with Child-Pugh B cirrhosis compared with those with Child-Pugh A cirrhosis (64 days vs 168 days, P = 0.004). Child-Pugh B cirrhosis (P = 0.024) and a high level of serum alpha-fetoprotein (P = 0.039) were independent risk factors for poor overall survival. Thirty-nine (34%) patients experienced grade 3/4 adverse events such as hand-foot skin reactions and diarrhea that required dose adjustment. CONCLUSIONS: The clinical outcomes of sorafenib-treated patients with advanced HCC were comparable to those reported by formal clinical trial conducted in the Asia-Pacific region. Underlying hepatic dysfunction was the most important risk factor for shorter survival.

Asunto(s)

Antineoplásicos/uso terapéutico , Carcinoma Hepatocelular/tratamiento farmacológico , Carcinoma Hepatocelular/patología , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Hepáticas/patología , Niacinamida/análogos & derivados , Compuestos de Fenilurea/uso terapéutico , Inhibidores de Proteínas Quinasas/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Antineoplásicos/efectos adversos , Carcinoma Hepatocelular/etiología , Carcinoma Hepatocelular/mortalidad , Femenino , Humanos , Neoplasias Hepáticas/etiología , Neoplasias Hepáticas/mortalidad , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Niacinamida/efectos adversos , Niacinamida/uso terapéutico , Compuestos de Fenilurea/efectos adversos , Pronóstico , Inhibidores de Proteínas Quinasas/efectos adversos , Estudios Retrospectivos , Factores de Riesgo , Sorafenib , Resultado del Tratamiento

RESUMEN

AIM: To identify factors affecting early local recurrence after transcatheter arterial chemoembolization (TACE) and investigate treatments and outcomes for local recurrence. METHODS: Early local recurrence and no early local recurrence groups drawn from 134 patients who were initially diagnosed with hepatocellular carcinoma (HCC) and showed a complete response (CR) to TACE treatment between January 1, 2006, and January 31, 2012, were analyzed by univariate and multivariate analyses. Additionally, the subsequent treatment for patients with recurrence was analyzed, and in cases in which TACE had been performed, the cumulative recurrence rates were calculated using the Kaplan-Meier method and compared with those of the primary lesion. RESULTS: The 1-, 2-, and 3-year survival rates were 92.3%, 60.2%, and 39.8%, respectively, in the early local recurrence group, which were significantly lower than those in both the late local and no local recurrence groups (P < 0.001). On multivariate analyses, non-compact lipiodol uptake, large tumor size, and an alpha-fetoprotein > 20 ng/mL after achieving a CR were significant predictors. When TACE was performed for early and late locally recurrent lesions, a CR was observed in 15 patients (41.7%) and 11 patients (78.6%), and the cumulative recurrence rates at 6, 12, and 24 mo were 17.9%, 43.3%, and 71.2%, respectively, which did not differ significantly from those after the first CR of 20.5%, 44.0%, and 58.6%, respectively (P = 0.639). CONCLUSION: Closer monitoring and active treatments must be provided to patients with risk factors for early local recurrence of HCC.

Asunto(s)

Carcinoma Hepatocelular/terapia , Quimioembolización Terapéutica , Neoplasias Hepáticas/terapia , Recurrencia Local de Neoplasia , Anciano , Carcinoma Hepatocelular/mortalidad , Carcinoma Hepatocelular/patología , Quimioembolización Terapéutica/efectos adversos , Quimioembolización Terapéutica/mortalidad , Femenino , Humanos , Estimación de Kaplan-Meier , Neoplasias Hepáticas/mortalidad , Neoplasias Hepáticas/patología , Modelos Logísticos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Oportunidad Relativa , Estudios Retrospectivos , Factores de Riesgo , Tasa de Supervivencia , Factores de Tiempo , Resultado del Tratamiento

RESUMEN

AIM: To investigate and compare the inhibitory effects of rapamycin in the different stages of liver fibrosis. METHODS: We performed bile duct ligation (BDL) in male Wistar rats (n = 24). The experimental rats were classified into four groups: the BDL(+)/Rapa(-) group (un-treated control, n = 4), the BDL(+)/Rapa(+) group (treated 14 d after BDL, n = 8), the BDL(+)/Rapa(++) group (treated on the day after BDL, n = 8), and the BDL(-)/Rapa(-) group (un-treated, sham -operated control, n = 4). The BDL(+)/Rapa(+) and BDL(+)/Rapa(++) groups were administered rapamycin (2 mg/kg) for 28 d. The liver tissues were tested by immunohistochemical staining for α-smooth muscle actin (α-SMA) and cytokeratin. RESULTS: The liver mRNA levels of transforming growth factor (TGF)-ß1 and platelet-derived growth factor (PDGF) were measured using the polymerase chain reaction. The protein levels of liver p70s6K and p-p70s6k were determined using Western blotting. α-SMA expression was lowest in the BDL(+)/Rapa(++)group. TGF-ß1 and PDGF expression levels in the rapamycin-treated group were lower than those in the un-treated group and higher than those in the control groups (TGF-ß1: 0.23 ± 0.00 vs 0.34 ± 0.01, 0.23 ± 0.0 vs 0.09 ± 0.00, P < 0.0001; PDGF: 0.21 ± 0.00 vs 0.34 ± 0.01, 0.21 ± 0.0 vs 0.09 ± 0.00, P < 0.0001). The p70s6k and p-p70s6k levels decreased in the treated groups and were lowest in the BDL(+)/Rapa(++)group (p70s6k: 1.05 ± 0.17 vs 1.30 ± 0.56, 0.40 ± 0.01 vs 1.30 ± 0.56, P < 0.0001; p-p70s6k: 1.40 ± 0.5 vs 1.67 ± 0.12, 0.70 ± 0.01 vs 1.67 ± 0.12, P < 0.0001). CONCLUSION: The results of our study indicate that rapamycin has inhibitory effects on liver fibrosis, and the treatment is most effective in the early stages of fibrosis.

Asunto(s)

Cirrosis Hepática Experimental/prevención & control , Hígado/efectos de los fármacos , Sirolimus/farmacología , Animales , Biomarcadores/sangre , Hígado/metabolismo , Hígado/patología , Cirrosis Hepática Experimental/sangre , Cirrosis Hepática Experimental/genética , Cirrosis Hepática Experimental/patología , Masculino , Fosforilación , Factor de Crecimiento Derivado de Plaquetas/genética , Factor de Crecimiento Derivado de Plaquetas/metabolismo , ARN Mensajero/metabolismo , Ratas Wistar , Proteínas Quinasas S6 Ribosómicas 70-kDa/metabolismo , Transducción de Señal/efectos de los fármacos , Factor de Crecimiento Transformador beta1/genética , Factor de Crecimiento Transformador beta1/metabolismo

RESUMEN

BACKGROUND/AIMS: The current study examines the expression of molecular biomarkers in hepatocellular carcinoma (HCC) and whether these findings correlate with the clinicopathologic features of the disease and patient survival. METHODS: We analyzed the immunohistochemical expression of p53, mammalian target of rapamycin (mTOR), c-Met, and insulin-like growth factor 1 receptor (IGF-1R) heat shock protein 70 (HSP70) with the clinicopathologic features of 83 HCCs. RESULTS: p53 expression was higher in the male patients with undifferentiated histological tumor grades, cirrhosis, and portal vein invasion. High 48 c-Met expression correlated with cirrhosis, and high mTOR expression correlated with the tumor grade and cirrhosis. High IGF-1R expression correlated with the tumor grade and cirrhosis. A multivariate analysis identified a significant relationship between the high expression of p53, tumor grade, and portal vein invasion. In addition, a high expression of mTOR was related to tumor grade and cirrhosis, and a high expression of HSP70 was related to portal vein invasion in a multivariate analysis. The Kaplan-Meier survival curve for patients with high versus low Edmondson grades and p53 expression was statistically significant. CONCLUSIONS: p53, mTOR, and IGF-1R expression correlated with the Edmondson tumor grade in a univariate analysis, while p53 and mTOR correlated with the Edmondson tumor grade in a multivariate analysis. In addition, the tumor grade was found to predict survival. p53 was primarily related to the clinicopathologic features compared to other markers, and it is a poor prognostic factor of survival.

Asunto(s)

Biomarcadores de Tumor/metabolismo , Carcinoma Hepatocelular/metabolismo , Neoplasias Hepáticas/metabolismo , Adulto , Anciano , Carcinoma Hepatocelular/cirugía , Supervivencia sin Enfermedad , Femenino , Proteínas HSP70 de Choque Térmico/metabolismo , Humanos , Neoplasias Hepáticas/cirugía , Masculino , Persona de Mediana Edad , Pronóstico , Proteínas Proto-Oncogénicas c-met/metabolismo , Receptor IGF Tipo 1/metabolismo , Estudios Retrospectivos , Factores de Riesgo , Serina-Treonina Quinasas TOR/metabolismo , Resultado del Tratamiento , Proteína p53 Supresora de Tumor/metabolismo

RESUMEN

Previous studies reported that oxaliplatin is associated with sinusoidal obstruction syndrome. However few reports on oxaliplatin induced liver fibrosis are found in the literature. Furthermore pathogenesis of liver fibrosis is not well known. We report a case of 45-yr-old Korean man in whom liver fibrosis with splenomegaly developed after 12 cycles of oxaliplatin based adjuvant chemotherapy for colon cancer (T4N2M0). Thorough history taking and serological examination revealed no evidence of chronic liver disease. Restaging CT scans demonstrated a good response to chemotherapy. Five month after chemotherapy, he underwent right hepatectomy due to isolated metastatic lesion. The liver parenchyma showed diffuse sinusoidal dilatation and centrilobular vein fibrosis with necrosis without steatosis. We could conclude that splenomegaly was due to perisinusoidal liver fibrosis and liver cell necrosis induced portal hypertension by oxaliplatin. In addition, to investigate the pathogenesis of liver fibrosis, immunohistochemical stains such as CD31 and α-smooth muscle actin (α-SMA) were conducted with control group. The immunohistochemical stains for CD31 and α-SMA were positive along the sinusoidal space in the patient, while negative in the control group. Chemotherapy with oxaliplatin induces liver fibrosis which should be kept in mind as a serious complication.

Asunto(s)

Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Camptotecina/análogos & derivados , Neoplasias del Colon/tratamiento farmacológico , Cirrosis Hepática/diagnóstico , Compuestos Organoplatinos/administración & dosificación , Esplenomegalia/diagnóstico , Actinas/metabolismo , Camptotecina/uso terapéutico , Quimioterapia Adyuvante , Fluorouracilo/uso terapéutico , Humanos , Hipertensión Portal/etiología , Inmunohistoquímica , Leucovorina/uso terapéutico , Cirrosis Hepática/etiología , Cirrosis Hepática/patología , Neoplasias Hepáticas/secundario , Neoplasias Hepáticas/cirugía , Masculino , Persona de Mediana Edad , Compuestos Organoplatinos/efectos adversos , Compuestos Organoplatinos/uso terapéutico , Oxaliplatino , Molécula-1 de Adhesión Celular Endotelial de Plaqueta/metabolismo , Esplenomegalia/etiología , Trombocitopenia/etiología , Tomografía Computarizada por Rayos X

RESUMEN

OBJECTIVES: For the geriatric population, upper reference limits (URLs) for alanine aminotransferase (ALT) levels have not been established. The aim of the study was to determine the URLs for ALT and to describe the factors associated with elevated ALT level in an elderly population. DESIGN AND METHODS: We set the URLs for ALT for participants aged 65 years and over (n=3646) based on the 2007-2009 Korea National Health and Nutrition Examination Survey at the 97.5th percentile of that population who were determined to be at low risk for liver disease (n=896; low risk was defined as testing negative for the HBs antigen, low alcohol intake, and the absence of metabolic syndrome, medical comorbidity, or medication use). RESULTS: The URLs for ALT were 39 IU/L for men and 30 IU/L for women. The weighted prevalence for the elevated ALT level was 8.0% (95% confidence interval [CI], 7.1% to 8.9%) in the sample, 5.8% (95% CI, 4.7% to 7.1%) in men and 9.5% (95% CI, 8.3% to 10.8%) in women. CONCLUSIONS: The URLs for ALT are established for the first time in the elderly, and our results may be useful for monitoring trends in the burden of liver disease, in addition to guiding the evaluation of ALT abnormalities in clinical practice.

Asunto(s)

Alanina Transaminasa/sangre , Hepatopatías/diagnóstico , Anciano , Pueblo Asiatico , Índice de Masa Corporal , Técnicas de Laboratorio Clínico/normas , Intervalos de Confianza , Bases de Datos Factuales , Femenino , Antígenos de Superficie de la Hepatitis B/sangre , Humanos , Hepatopatías/epidemiología , Masculino , Encuestas Nutricionales , Prevalencia , Valores de Referencia , República de Corea/epidemiología , Factores de Riesgo

RESUMEN

BACKGROUND: Despite suggestions to lower the upper reference limits (URL) for aminotransferase activities to increase the detection of liver disease, there is no generally accepted URL in the general Korean population. METHODS: We set the URL for alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities at the 97.5th percentile in a population at low risk for liver disease (n=3316; negative HBs antigen, low alcohol intake, normal waist circumference, normal lipid or carbohydrate metabolism, and absence of medication use) derived from the 2007 to 2009 Korean National Health and Nutrition Examination Survey (KNHANES; n=16,608). RESULTS: The URLs for ALT activity were 53 IU/L for men and 30 IU/L for women, and the corresponding limits for AST activity were 37 IU/L for men and 29 IU/L for women. The age-adjusted prevalence of the elevated ALT activity was 8.6% [95% confidence interval (CI), 8.2%-9.1%] in the 2007 to 2009 KNHANES and 6.9% (95% CI, 6.3%-7.5%) in the 2001 KNHANES, a relative increase of 24.6% (P<0.05). This increase was concentrated among those aged 20 to 29, with a relative increase of 66.7%, and those aged 30 to 39, with a relative increase of 54.4%. There was no significant change in the prevalence of elevated AST activity. CONCLUSIONS: The URL for ALT activity among the general Korean population is clearly higher than recently proposed thresholds. The trajectory of the increasing prevalence of elevated ALT activity heralds an increased burden of chronic liver disease in the future Korean population.

Asunto(s)

Alanina Transaminasa/sangre , Pueblo Asiatico/estadística & datos numéricos , Aspartato Aminotransferasas/sangre , Hepatopatías/diagnóstico , Hepatopatías/enzimología , Adulto , Biomarcadores/sangre , Estudios Transversales , Femenino , Encuestas Epidemiológicas , Humanos , Hepatopatías/epidemiología , Masculino , Encuestas Nutricionales , Prevalencia , Valores de Referencia , República de Corea/epidemiología , Factores de Riesgo

RESUMEN

BACKGROUND/AIMS: The incremental usefulness of adding hepatic venous pressure gradient (HVPG) for predicting the risk of death has not, to our knowledge, been evaluated among patients with decompensated cirrhosis. We investigated whether the incorporation of the HVPG in an established model improved the prediction of death in a cohort of decompensated cirrhosis patients. METHODOLOGY: We used data from 106 consecutive patients with decompensated cirrhosis who underwent a hemodynamic study between January 2006 and December 2007, to investigate whether the HVPG improved the risk discrimination of a patient beyond an assessment that was based on the Model for End-stage Liver Disease (MELD) or MELD-Na. We used occurrence vs. non-occurrence of events within 12 months as the outcome for analysis. RESULTS: For prediction of 12 months survival, the area under the receiver-operating characteristic curve (AUROC) for the MELD-Na was significantly greater than that of the MELD (79.4% vs. 70.5%, p=0.05). The MELD performed similar to the HVPG (70.5% vs. 71.2%, p=0.471). Adding the HVPG measurement to the MELD or the MELD-Na did not result in significant increase of the AUROC,with only a small improvement of about 5% in both cases. CONCLUSIONS: The MELD-Na is the most predictive for 12-month survival in patients with decompensated cirrhosis. The addition of the HVPG to the MELD or the MELD-Na score does not appear to improve the prognostic accuracy of the MELD or the MELD-Na score significantly.

Asunto(s)

Técnicas de Apoyo para la Decisión , Venas Hepáticas/fisiopatología , Cirrosis Hepática/diagnóstico , Cirrosis Hepática/mortalidad , Presión Venosa , Adulto , Anciano , Biomarcadores/sangre , Determinación de la Presión Sanguínea , Análisis Discriminante , Femenino , Humanos , Cirrosis Hepática/sangre , Cirrosis Hepática/complicaciones , Cirrosis Hepática/fisiopatología , Modelos Logísticos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Valor Predictivo de las Pruebas , Pronóstico , Curva ROC , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Sodio/sangre , Análisis de Supervivencia , Factores de Tiempo

RESUMEN

The Alcohol Use Disorders Identification Test (AUDIT) has been found to provide an accurate measure for risk of hazardous and harmful alcohol use, as well as possible dependence. Data from 2 representative samples of 7693 adults in the Korea National Health and Nutrition Examination Survey (KNHANES) 2005 and 6276 participants in 2009 were analyzed. The overall age-adjusted prevalence of alcohol use disorder (AUD) in 2009 (38.8%) was higher than that in 2005 (32.7%), with a difference of 6.1% (95% confidence interval [CI], 2.9%-9.3%; P = .0002). Men were about 7 times as likely as women to meet the criteria for AUD (odds ratio [OR] = 7.16; 95% CI, 6.27-8.17). Current smoking was the most important correlate associated with AUD in both genders (women: OR = 6.03; 95% CI, 4.40-8.27; men: OR = 2.83; 95% CI, 2.29-3.48). Among women, unmarried (OR = 1.76; 95% CI, 1.35-2.31), less than high school education (OR = 2.71, 95% CI, 1.86-3.96), and lowest income (OR = 1.45, 95% CI, 1.06-1.97) were associated with AUD. These findings provide the most updated prevalence estimates of AUD in the Korean population and they highlight its strong association with smoking, gender differences, and lower socioeconomic status in the Korean population.

Asunto(s)

Trastornos Relacionados con Alcohol/epidemiología , Pueblo Asiatico/psicología , Encuestas Nutricionales/tendencias , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Encuestas Nutricionales/estadística & datos numéricos , Prevalencia , República de Corea/epidemiología , Factores de Riesgo , Caracteres Sexuales , Fumar/epidemiología , Clase Social

RESUMEN

Pulmonary tuberculosis is an opportunistic infection that can be reactivated in immunocompromised conditions, for example, in malignancy or after liver transplantation. Hepatocellular carcinoma (HCC) has a high mortality rate because it is frequently diagnosed at an advanced stage. Although surgical resection is the established curative measure for HCC, it is only feasible for early-stage HCC. Transcatheter arterial chemoembolization (TACE) is the most common treatment modality for patients with unresectable HCC. However, repeated TACE sessions and, occasionally, the tumor itself can further impair the reserve hepatic function and immunity. We report 3 recent cases of HCC with reactivation of pulmonary tuberculosis after TACE.

RESUMEN

BACKGROUND: Hepatocellular carcinoma (HCC) screening has been recommended for hepatitis B virus (HBV)-infected individuals in an effort to detect HCC at a sufficiently early stage to provide potentially curative treatments. The study reported here is the first to address the rate of HCC screening use in an HBV endemic area. METHODS: Data were collected from 11,147 adults aged ≥40 years who participated in the 2007-2009 Korea National Health and Nutrition Examination Survey and had a valid HBV surface antigen test. Current HCC screening was defined as either receiving an ultrasonography or an α-fetoprotein measurement in the past year. Prevalence estimates were weighted. RESULTS: The response rate was 78.4 %, and 436 cases of HBV infection were identified. The overall seroprevalence of the HBV surface antigen was 4.1 % [95 % confidence interval (CI) 3.9-4.4 %]. Of the 436 HBV-infected subjects, only 23.2 % (95 % CI 19.5 -27.4 %) were aware that they had been infected, and approximately 27 % (27.1 %; 95 %CI 23.2-to 31.5 %) were up to date with their HCC screening tests; more than half (52.9 %, 95 % CI 48.2-57.5) had never been screened. In a multivariate analysis that included various sociodemographic variables, only self-reported awareness of HBV infection was significantly associated with current HCC screening tests (odds ratio 2.82; 95 % CI 1.64-4.84). CONCLUSIONS: Adoption of HCC screening as a standard practice among HBV-infected Korean adults aged ≥40 years is suboptimal. Evidence-based programs in communities and education for both healthcare providers and HBV-infected persons are needed to improve the implementation of HCC screening in clinical practice.

Asunto(s)

Carcinoma Hepatocelular/diagnóstico , Hepatitis B/complicaciones , Neoplasias Hepáticas/diagnóstico , Adulto , Carcinoma Hepatocelular/epidemiología , Carcinoma Hepatocelular/etiología , Estudios Transversales , Femenino , Encuestas Epidemiológicas , Hepatitis B/virología , Antígenos de Superficie de la Hepatitis B/sangre , Virus de la Hepatitis B , Humanos , Neoplasias Hepáticas/epidemiología , Neoplasias Hepáticas/etiología , Masculino , Tamizaje Masivo , Oportunidad Relativa , República de Corea/epidemiología , Factores de Riesgo , Estudios Seroepidemiológicos

RESUMEN

AIM: To evaluate the treatment outcomes of clevudine compared with entecavir in antiviral-naive patients with chronic hepatitis B (CHB). METHODS: We retrospectively analyzed the clinical data of CHB patients treated with clevudine 30 mg/d and compared their clinical outcomes with patients treated with entecavir 0.5 mg/d. The biochemical response, as assessed by serum alanine aminotransferase (ALT) activity, virologic response, as assessed by serum hepatitis B virus DNA (HBV DNA) titer, serologic response, as assessed by hepatitis B e antigen (HBeAg) status, and virologic breakthrough with genotypic mutations were assessed. RESULTS: Two-hundred and fifty-four patients [clevudine (n = 118) vs entecavir (n = 136)] were enrolled. In clevudine-treated patients, the cumulative rates of serum ALT normalization were 83.9% at week 48 and 91.5% at week 96 (80.9% and 91.2% in the entecavir group, respectively), the mean titer changes in serum HBV DNA were -6.03 and -6.55 log(10) copies/mL (-6.35 and -6.86 log(10) copies/mL, respectively, in the entecavir group), and the cumulative non-detection rates of serum HBV DNA were 72.6% and 83.1% (74.4% and 83.8%, respectively, in the entecavir group). These results were similar to those of entecavir-treated patients. The cumulative rates of HBeAg seroconversion were 21.8% at week 48 and 25.0% at week 96 in patients treated with clevudine, which was similar to patients treated with entecavir (22.8% and 27.7%, respectively). The virologic breakthrough in the clevudine group occurred in 9 (7.6%) patients at weeks 48 and 15 (12.7%) patients at week 96, which primarily corresponded to genotypic mutations of rtM204I and/or rtL180M. There was no virologic breakthrough in the entecavir group. CONCLUSION: In antiviral-naive CHB patients, long-term treatment outcomes of clevudine were not inferior to those of entecavir, except for virologic breakthrough.

Asunto(s)

Antivirales/farmacología , Arabinofuranosil Uracilo/análogos & derivados , Hepatitis B Crónica/tratamiento farmacológico , Adulto , Alanina Transaminasa/metabolismo , Arabinofuranosil Uracilo/farmacología , ADN Viral/análisis , Femenino , Genotipo , Guanina/análogos & derivados , Guanina/farmacología , Virus de la Hepatitis B/genética , Humanos , Masculino , Persona de Mediana Edad , Mutación , Estudios Retrospectivos , Resultado del Tratamiento

RESUMEN

BACKGROUND: It is unclear to what extent insulin resistance (IR) modulates the association linking obesity to alanine aminotransferase (ALT) activity elevation. METHODS: We measured the homeostatic model assessment for IR (HOMA-IR) in 1591 participants aged 12-18 years from the 2008 to 2009 Korea National Health and Nutrition Examination Survey. RESULTS: Overweight adolescents had an odds ratio of 7.23 [95% confidence interval (95% CI), 4.33-12.10] for an elevated ALT activity compared with normal-weight adolescents, and the corresponding risk was 23.62 (95% CI, 12.98-42.98) in obese adolescents. Adjustments for other participant factors did not substantially affect the results. The addition of the HOMA-IR data decreased the estimate for overweight adolescents by 27% and for obese adolescents, the decrease was 47%. Both obesity and IR markers remained independent predictors of outcome. CONCLUSIONS: The greater the obesity level, the more that IR contributes to the association between obesity and an elevated ALT activity.

Asunto(s)

Alanina Transaminasa/sangre , Resistencia a la Insulina , Obesidad/complicaciones , Adolescente , Estudios Transversales , Hígado Graso/etiología , Femenino , Humanos , Corea (Geográfico) , Masculino , Enfermedad del Hígado Graso no Alcohólico , Factores de Riesgo

RESUMEN

BACKGROUND/AIMS: This study was conducted to investigate the assessment of treatment efficacy of radiotherapy (RT) and other therapeutic modalities compared with palliative care only for treatment with advanced hepatocellular carcinoma (HCC). METHODS: From 2002 to 2010, based on the case of 47 patients with advanced HCC, we have investigated each patients' Child-Pugh's class, ECOG performance, serum level of alpha fetoprotein and other baseline characteristics that is considered to be predictive variables and values for prognosis of HCC. Out of overall patients, the 29 patients who had received RT were selected for one group and the 18 patients who had received only palliative care were classified for the other. The analysis in survival between the two groups was done to investigate the efficacy of RT. RESULTS: Under the analysis in survival, the mean survival time of total patients group was revealed between 30.1 months and 45.9 months in RT group, while it was 4.8 months in palliative care group, respectively. In the univariate analysis for overall patients, there were significant factors which affected survival rate like as follows: ECOG performance, Child-Pugh's class, the tumor size, the type of tumor, alpha fetoprotein, transarterial chemoembolization, and RT. The regressive analysis in multivariate Cox for total patients. No treatment under radiotherapy and high level of Child-Pugh's class grade were independent predictors of worse overall survival rate in patients. In contrast, for the subset analysis of the twenty-nine patients treated with radiotherapy, the higher serum level of alpha fetoprotein was an independent predictors of worse overall survival rate in patients. CONCLUSIONS: We found that the survival of patients with advanced HCC was better with radiotherapy than with palliative care. Therefore, radiotherapy could be a good option for in patients with advanced HCC.

Asunto(s)

Carcinoma Hepatocelular/radioterapia , Neoplasias Hepáticas/radioterapia , Cuidados Paliativos , Anciano , Carcinoma Hepatocelular/mortalidad , Carcinoma Hepatocelular/patología , Quimioembolización Terapéutica , Estudios de Cohortes , Femenino , Humanos , Neoplasias Hepáticas/mortalidad , Neoplasias Hepáticas/patología , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Análisis de Supervivencia , alfa-Fetoproteínas/análisis

RESUMEN

BACKGROUND/AIM: Alcohol consumption continues to be a common cause of acute and chronic liver disease. METHODS: Data from a representative sample of 7,893 adults in the Korean National Health and Nutrition Examination Survey 2009 were analyzed. Alcoholic liver disease (ALD) was defined through heavy alcohol consumption (≥40 g/day for men or ≥20 g/day for women) and through elevated liver tests. RESULTS: Approximately 6.7% (95% confidence interval [CI], 6.0-7.4) was at heavy alcohol consumption. Of these "heavy alcohol consumers", one quarter also had ALD. The prevalence of ALD was 1.7% (95% CI, 1.3-2.1). CONCLUSION: ALD is still a burden in the Korean population.

Asunto(s)

Consumo de Bebidas Alcohólicas/epidemiología , Alcoholismo/epidemiología , Hepatopatías Alcohólicas/epidemiología , Adulto , Anciano , Anciano de 80 o más Años , Estudios Transversales , Femenino , Encuestas Epidemiológicas , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , República de Corea/epidemiología , Factores Sexuales

RESUMEN

BACKGROUND/AIMS: The combination therapy with peginterferon and ribavirin is a standard treatment for patients with chronic hepatitis C. However, because of the long duration of the treatment and many complications, the reduction of adherence frequently occur. This study aimed to assess influences of reduced medication adherence in the combination therapy of chronic hepatitis C patients. METHODS: We retrospectively reviewed the medical records of 82 patients with chronic hepatitis C who received a combination therapy with peginterferon and ribavirin. The patients were categorized into 3 subgroups on the basis of medication adherence. Group 1 comprised patients who received ≥80% of the recommended dosage of both peginterferon and ribavirin. Group 2 comprised those patients who received ≥80% of the recommended dosage of only 1 drug. The patients of Group 3 received <80% of the recommended dosage of both the drugs. RESULTS: Sustained virologic response (SVR)s of patients in Group 1, 2 and 3 were 85.4% (41/48), 85.7% (18/21), and 38.5% (5/13), respectively (p=0.002). SVRs of genotype 1 patients in Group 1, 2 and 3 were 84.2% (16/19), 75% (9/12), and 14.3% (1/7) , respectively (p=0.003). SVRs of genotype non-1 patients in Group 1, 2 and 3 were 86.2% (25/29), 100% (9/9), and 66.7% (4/6), respectively (p=0.196). Furthermore are SVRs significantly differed with the degree of medication adherence to either peginterferon or ribavirin (p=0.003 and 0.021, respectively). In multivariate analysis, the peginterferon dose was a significant independent factor associated with SVR. CONCLUSIONS: Medication adherence of chronic hepatitis C patients to the combination therapy with peginterferon and ribavirin is very important for achieving SVR. In particular, we think that genotype 1 patients should maintain higher adherence than genotype non-1 patients.

Asunto(s)

Antivirales/uso terapéutico , Hepatitis C Crónica/tratamiento farmacológico , Interferón-alfa/uso terapéutico , Cumplimiento de la Medicación , Polietilenglicoles/uso terapéutico , Ribavirina/uso terapéutico , Adulto , Quimioterapia Combinada , Femenino , Genotipo , Humanos , Interferón alfa-2 , Masculino , Persona de Mediana Edad , ARN Viral/análisis , Proteínas Recombinantes , Estudios Retrospectivos

RESUMEN

AIM: To investigate how many discrepancies occur in patients before and after endoscopic treatment of referred adenoma and the reason for these results. METHODS: We retrospectively reviewed data from 554 cases of 534 patients who were referred from primary care centres for adenoma treatment and treated for endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) at Chungnam National University Hospital, from July 2006 to June 2009. Re-endoscopy was examined in 142 cases and biopsy was performed in 108 cases prior to treatment. Three endoscopists (1, 2 and 3) performed all EMRs or ESDs and three pathologists (1, 2 and 3) diagnosed most of the cases. Transfer notes, medical records and endoscopic pictures of these cases were retrospectively reviewed and analyzed. RESULTS: Adenocarcinoma was 72 (13.0%) cases in total 554 cases after endoscopic treatment of referred adenoma. When the grade of dysplasia was high (55.0%), biopsy number was more than three (22.7%), size was no smaller than 2.0 cm (23.2%), morphologic type was depressed (35.8%) or yamada type IV (100%), and color was red (30.9%) or mixed-or-undetermined (25.0%), it had much more malignancy rate than the others (P < 0.05). All 18 cases diagnosed as adenocarcinoma in the re-endoscopic forceps biopsy were performed by endoscopist 1. There were different malignancy rates according to the pathologist (P = 0.027). CONCLUSION: High grade dysplasia is the most important factor for predicting malignancy as a final pathologic diagnosis before treating the referred gastric adenoma. This discrepancy can occur mainly through inappropriately selecting a biopsy site where cancer cells do not exist, but it also depends on the pathologist to some extent.

Asunto(s)

Adenoma/diagnóstico , Adenoma/patología , Adenoma/cirugía , Gastroscopía/métodos , Neoplasias Gástricas/diagnóstico , Neoplasias Gástricas/patología , Neoplasias Gástricas/cirugía , Adenocarcinoma/diagnóstico , Adenocarcinoma/patología , Adenocarcinoma/cirugía , Anciano , Biopsia/métodos , Femenino , Humanos , Hiperplasia/patología , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo

RESUMEN

BACKGROUND/AIMS: Clevudine, a pyrimidine nucleoside analogue, has potent antiviral effects in patients with chronic viral hepatitis B (CHB). We report the efficacy of initial treatment with clevudine in naïve patients with CHB living in Daejeon and Chungcheong Province, South Korea. METHODS: One hundred five adults with CHB were administered 30 mg of clevudine per day for an average of 51 weeks. We evaluated viral markers and liver biochemistry retrospectively every 3 months. RESULTS: Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and hepatitis B virus (HBV) DNA before the treatment were 184 ± 188 IU/L, 150 ± 138 IU/L, and 7.1 ± 1.2 log copies/mL, respectively. Undetectable rates (< 60 IU/mL) of DNA were 36.2%, 68.9%, 83.6%, 76.2%, and 75.8% at 12, 24, 36, 48, and 60 weeks, respectively. Seroconversion rates were 9.1%, 13.6%, 24.6%, 26.5%, and 26.1% and ALT normalization rates were 64.5%, 78.1%, 87.9%, 90.0% at 12, 24, 36, and 48 weeks, respectively. Six patients (5.7%) had a viral breakthrough. CONCLUSIONS: Clevudine is a useful drug in the initial treatment of patients with CHB, with a potent antiviral effect and low incidence of viral breakthrough.

Asunto(s)

Antivirales/uso terapéutico , Arabinofuranosil Uracilo/análogos & derivados , Adulto , Alanina Transaminasa/sangre , Arabinofuranosil Uracilo/uso terapéutico , Femenino , Antígenos e de la Hepatitis B/sangre , Hepatitis B Crónica/tratamiento farmacológico , Hepatitis B Crónica/virología , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos